The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis

Nature Genetics

Volumn 48, Issue 8, 2016, Pages 848-855

  Gibson, William J ^a,b,c   Hoivik, Erling A ^d,e   Halle, Mari K ^d,e   Taylor Weiner, Amaro ^a   Cherniack, Andrew D ^a   Berg, Anna ^d,e   Holst, Frederik ^a,b,d,e   Zack, Travis I ^a,b,c   Werner, Henrica M J ^d,e   Staby, Kjersti M ^e   Rosenberg, Mara ^a   Stefansson, Ingunn M ^d,e   Kusonmano, Kanthida ^d,e,h   Chevalier, Aaron ^a   Mauland, Karen K ^d,e   Trovik, Jone ^d,e   Krakstad, Camilla ^d,e   Giannakis, Marios ^a,b   Hodis, Eran ^a,b,c   Woie, Kathrine ^d   Bjorge, Line ^d,e   Vintermyr, Olav K ^d,e   Wala, Jeremiah A ^a,b,c   Lawrence, Michael S ^a   Getz, Gad ^a   Carter, Scott L ^a,b,f,g   Beroukhim, Rameen ^a,b,c   Salvesen, Helga B ^d,e   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d UNIVERSITY OF BERGEN   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h KING MONGKUT'S UNIVERSITY OF TECHNOLOGY THONBURI   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINOPELVIC METASTASIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ESTROGEN RECEPTOR COFACTOR GENE; EXOME; FEMALE; GENE; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOME; GENOMICS; HUMAN; HUMAN TISSUE; HYPERPLASIA; MAJOR CLINICAL STUDY; METASTASIS; MUTATION; NRIP1 GENE; PHYLOGENY; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR BIOPSY; ABDOMINAL TUMOR; DISEASE COURSE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR EVOLUTION; PATHOLOGY; PELVIS TUMOR; SECONDARY;

TUMOR MARKER;

ABDOMINAL NEOPLASMS; BIOMARKERS, TUMOR; DISEASE PROGRESSION; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; EVOLUTION, MOLECULAR; EXOME; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PELVIC NEOPLASMS; PHYLOGENY;

EID: 84976286781     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3602     Document Type: Article

References (53)

1. Bhaskaran, K. et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384, 755-765 (2014)
2. Bokhman, J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15, 10-17 (1983)
3. The Cancer Genome Atlas Research Network. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013)
4. Salvesen, H.B. et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc. Natl. Acad. Sci. USA 106, 4834-4839 (2009)
5. Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105, 8713-8717 (2008)
6. Salvesen, H.B., Haldorsen, I.S. &Trovik, J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol. 13, e353-e361 (2012)
7. Ciriello, G. et al. Emerging landscape of oncogenic signatures across human cancers. Nat. Genet. 45, 1127-1133 (2013)
8. Giannakis, M. et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat. Genet. 46, 1264-1266 (2014)
9. Lawrence, M.S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014)
10. Woodruff, J.D. &Pickar, J.H. The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am. J. Obstet. Gynecol. 170, 1213-1223 (1994)
11. Veeraraghavan, J. et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat. Commun. 5, 4577 (2014)
12. Cavaillès, V. et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14, 3741-3751 (1995)
13. Rosell, M. et al. Complex formation and function of estrogen receptor α in transcription requires RIP140. Cancer Res. 74, 5469-5479 (2014)
14. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013)
15. Robinson, D.R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013)
16. Kamburov, A. et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc. Natl. Acad. Sci. USA 112, E5486-E5495 (2015)
17. Chang, M.T. et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155-163 (2016)
18. Novetsky, A.P. et al. Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol. Oncol. 128, 470-474 (2013)
19. Hong, B., Le Gallo, M. &Bell, D.W. The mutational landscape of endometrial cancer. Curr. Opin. Genet. Dev. 30, 25-31 (2015)
20. Ren, Y. et al. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci. Rep. 3, 3042 (2013)
21. Hayes, M.P. et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 12, 5932-5935 (2006)
22. Brastianos, P.K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164-1177 (2015)
23. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012)
24. Ganem, N.J., Godinho, S.A. &Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282 (2009)
25. Zack, T.I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013)
26. Stachler, M.D. et al. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat. Genet. 47, 1047-1055 (2015)
27. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015)
28. Wright, J.D., Barrena Medel, N.I., Sehouli, J., Fujiwara, K. &Herzog, T.J. Contemporary management of endometrial cancer. Lancet 379, 1352-1360 (2012)
29. Mao, T.L. et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am. J. Surg. Pathol. 37, 1342-1348 (2013)
30. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013)
31. Lohr, J.G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91-101 (2014)
32. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008)
33. Zhao, S. et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl. Acad. Sci. USA 110, 2916-2921 (2013)
34. Campbell, P.J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010)
35. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010)
36. McFadden, D.G. et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298-1311 (2014)
37. Ghoussaini, M. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat. Genet. 44, 312-318 (2012)
38. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014)
39. Johnson, B.E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343, 189-193 (2014)
40. Abedalthagafi, M.S. et al. ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 208, 345-350 (2015)
41. Torres-Martín, M. et al. Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules. Cancer Genet. 208, 327-332 (2015)
42. Lee, R.S. et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983-2988 (2012)
43. Bitler, B.G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231-238 (2015)
44. Werner, H.M. et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod. Pathol. 26, 428-434 (2013)
45. Wiegand, K.C. et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J. Pathol. 224, 328-333 (2011)
46. Kim, M.Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009)
47. Valastyan, S. &Weinberg, R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275-292 (2011)
48. Berg, A. et al. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget 6, 1327-1339 (2015)
49. Wik, E. et al. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecol. Oncol. 134, 599-606 (2014)
50. Saunders, C.T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811-1817 (2012)
51. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013)
52. Costello, M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res. 41, e67 (2013)
53. Zhu, S., Degnan, J.H. &Steel, M. Clades, clans, and reciprocal monophyly under neutral evolutionary models. Theor. Popul. Biol. 79, 220-227 (2011)